NCT07344051

A Phase II Study of QLS12010 Capsules in Adults With Moderate to Severe Atopic Dermatitis

A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial Evaluating the Efficacy and Safety of QLS12010 Capsules in Adult Participants With Moderate-to-Severe Atopic Dermatitis

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 160 (estimated)
• Sponsor: Qilu Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This trial was designed to evaluate the efficacy and safety of QLS12010 Capsules in adults with moderate-to-severe atopic dermatitis.

Conditions

• Moderate-to-severe Atopic Dermatitis

Interventions

Type	Name	Description
DRUG	QLS12010	QLS12010 oral capsule
DRUG	Placebo	Matching placebo oral capsule

Timeline

• Start date: 2026-04-05
• Primary completion: 2027-09-01
• Completion: 2027-09-01
• First posted: 2026-01-15
• Last updated: 2026-01-15